Updated overall survival (OS) from extended follow up in...

Annals of Oncology 2019 / 11 Vol. 30

Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations

Mok, T.S.K., Cheng, Y., Zhou, X., Lee, K.H., Nakagawa, K., Niho, S., Linke, R., Rosell, R., Corral, J., Migliorino, M.R., Pluzanski, A., Noonan, K., Tang, Y., Wilner, K.D., Wu, Y.-L.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz446.018
Date:
November, 2019
File:
PDF, 102 KB
2019
Conversion to is in progress
Conversion to is failed